The international PHM aims to achieve universal health coverage and access to quality healthcare by 2030, as the WHO and UN Sustainable Development Goals execute an agenda that emphasizes the importance of ecosystem strengthening to achieve targets (World Health Organization, 2023). The US Healthy People 2030 and UK People Plan set national aims to improve health and well-being (Office of Disease Prevention and Health Promotion, 2024; NHS England, 2020). However, reforming the PHM transformation infrastructure performance program by 2030 using AI policy for UK-US healthcare reform presents challenges, which HEMSS principles address to accelerate “classical” HPO in both countries (Infrastructure and Projects Authority, 2021; Center for AI and Digital Policy, n.d.).

Figure 2 provides an overview of the strategic proposal with the strategy for “Population Health Management Higher Expert Medical Science Safety Agile Group Development” as the perspective for HPO risk stratification to predict wellbeing and action disease segmentation for target intercepts by engineering public safety. These are presented in Section 1.3.2 of the US and UK AI strategy for Population Health Management and Section 1.3.3 of the Higher Expert Medical Science Safety Agile Group Development. In Section 1.3.4, HPO outlines predictor pre-eXams and precise care eXams classification, and Section 1.3.5 contains Ontology System Engineering Initiatives for Public Safety.

The US Center for AI and Digital Policy (CAIDP) may achieve a better society by ensuring that technology promotes broad social inclusion through fundamental rights, democratic institutions, and the rule of law (Center for AI and Digital Policy, n.d.). Executive orders support US national plans for AI, including advancing leadership and harnessing national security, safety, and trust (The White House, 2023). Nevertheless, data solutions that develop enterprises with plans are not adequately equipped to reform the PHM of the HPO as a national strategy (Admin, 2024).

The UK Government’s DSIT global strategy scales safer and more responsible AI plans and actions (UK Government, 2021), but is not yet prepared for PHM reform through governed classification. Long-term NHSE plans for genomics and social models require ecosystem HPO-enabled predictors and intercept classifiers to benefit sectors and regions (Chapman and Middleton, 2019; Care planning, 2024). DSIT healthcare, scientific research, and digital transformation for the PHM of HPO use biological models for well-being with data-driven plans for proactive care (GOV.UK and DSIT, 2024). The HEMSS classifies valid pre-eXams and eXams to facilitate multicomplex model integration and simplify it using agile methodologies.

The UK-US PHM reform integrates HPO in joint NIST/AISI biological [Gen AI-X] models with national digital QA in neighborhood clinics or federal centers, which define innovation and culture pre-eXam/eXam classifiers for the Brightest Tomorrow (Kosiol et al., 2024; NIST, 2024). Figure 2 illustrates a conceptual PHM ecosystem proposed with HEMSS for deploying HPO-driven solutions that enhance healthcare delivery and improve patient outcomes; under national government authorities and directorship. This HEMSS initiative, envisioned as an executive arm of a corporate agile group development program, would aim to ensure the ethical use of the genome predictor pre-eXam for eXams intercepts, as personalized classifiers integrate the PHM ecosystem [X = Gen AI].

In Figure 1, the PHM is shown to transform primary care through HEMSS standards and tools. Agile groups have developed the NHSE Genomics and AISI evaluations for the adoption of AIDRS classifications for public health and patient safety. HEMSS aligns Healthcare Information Management System Society [HIMSS] norms in PHM governance in an ecosystem that adopts valid HPO (Healthcare Information and Management Systems Society, 2019). The UK AIDRS has developed NHSE HPO adoption in national clinical pathway agreements on fit-for-purpose pre-eXams/eXams across FDPs as HEMSS/HIMSS advances PHM maturity from 2025 (DHI Newsteam, 2022; Burrell, 2023).

In Figure 2, the upper circle informs the Human Phenotype Ontology Policy for UK Clinics and US Centers, which provides oversight of Value-Based Care at the point of need, while the smaller circle is under the authority of AIDRS and HEMSS. Figure 2 depicts the HEMSS HPO-centeredness with Gen AI = X for PHM deployment in genomic health pre-eXams and biopharma eXam intercepts, where HEMSS tools and principles encircle health providers and partners from left to right.

Table 1 illustrates the HEMSS with Agile Group Development, in which the PHM adopts HPO risk stratification for disease segmentation. Establishing a pilot in a UK ICB region does not preclude expansion, with the success of a pilot facilitating similar initiatives in the US that integrate HPO biological systems from neighborhood clinics to federal centers (NIST, 2024). Cross-national collaboration enhances PHM using advanced HPO technologies and ensures consistent improvements across both countries in a MoU on AI for PHM (UK.GOV, 2024).

In Figure 1, the three towers are shown to develop agile GEN AI with the adoption of HPO primary care reform as an ecosystem that extends beyond the standard vocabulary. The author showcases pre-eXams and eXams using Gen-AI to predict human phenotypic abnormalities and target ontology intercepts related to standard traits or characteristics, with digital recommendations for optimal interventions. This manuscript assesses the actions and discusses the aims of biological modelling with socio-environmental elements for HPO ecosystem.

As shown in Figure 2, an HPO genome blueprint predicts and intercepts pathology in digital records that align pre-eXams with lifetime eXams for effective healthcare based on patient profiles. The flow of accurate eXams from HPO pre-eXam classifiers tailors the effective biopharma and socio-environmental intercepts. The post-eXam data refines the nodes with backpropagation for continual improvements. X alerts adoption, whereas X pre-exams/exams are not authorized for commission. An X could be invalid for multiple reasons, such as poor data training, unverified AI-QA, or excessive biopharmaceutical costs.

In Figure 2, in the lower circle, HPO System Engineering Initiatives for Public Safety (OSEIPS) is a proposal that aligns Population Health Management Higher Medical Science Safety Agile Group Development as the program proposal for the NHSE, Genomics England and the Life Science Sector to realize safe spaces. System Engineering Initiatives for Patient Safety (SEIPS) v 3.0 and SEIPS v 2.0 improve outcomes by applying principles from human factors and system thinking and understanding the interaction of the environment, tools, tasks, and people (Carayon et al., 2020; Holden et al., 2013).

In Figure 2, the bullet points across four healthcare sectors are detailed that impact patient safety, whereby the UK National Patient Safety Policy for NHSE recommends using SEIPS to learn from patient safety events (NHS England, 2019). The Patient Safety Incident Response Framework incorporates SEIPS to analyze and improve outcomes while Learning from Patient Safety Events (NHS England, n.d.a; NHS England, n.d.b). The Healthcare Safety Investigation Branch uses SEIPS as a monitoring tool to ensure comprehensive investigations and system-based improvements (GOV.UK, 2022).

Figure 2 depicts the UK-US PHM AI aim for value-based care at the point of need across ICBs and CMS with HEMSS agile group development of HPO risk stratification and disease segmentation. The left-hand side of Figure 3 shows the well-being and welfare assessments encapsulating the PHM, with each step explained as follows. Section 1.3.7 details biobank opportunities for value-based care. Section 1.3.8 outlines PHM risk stratification of disease segmentation and real-world HPO instances. Section 1.3.9 evaluates the standard approaches for PHM, and Section 1.3.10 assesses the toolkit approaches for HPO.

The UK-US PHM national genome studies with socioenvironmental factors have advanced HPO value-based care (HM Government, 2020; National Institutes of Health, 2019). UK PHM could solve medical challenges through programs such as the “Generation Study,” which sequences newborn genomes to identify rare genetic diseases, or the “Our Future Health” program, which collects health and lifestyle data for disease prevention and treatment of major conditions (Horton et al., 2024; Our Future Health and NHS, 2022). In the US, the “Million Veterans Program” collects genetic and health data to study how genes affect health, whilst the “All of Us” program gathers data and reaches out to partners to predict HPO and intercept pathology for well-being (Gaziano et al., 2016; NIH, 2024).

PHM biobank value-based care requires a normal toolkit approach to challenge opportune genome analysis, which classifies real-world HPO solutions (Oxford Academic Press, 2024). Literacy in predictive health biobanks from biological samples also models precision medicine, while the future direction classifies HPO predictors and intercepts for governance (Annaratone et al., 2021; Coppola et al., 2019). Biobanking now addresses complex predictive health and precision care in settings with evidence-based, real-world risk stratification and disease segmentation standards and tools to implement the national PHM successfully using the HEMSS task force (Vaught, 2021; Ede et al., 2024).

UK ICB assessments and US Centers for Medicare and Medicaid Services surveys for HPO developments require digital directories and modelling (N. England, 2023; CMS.GOV, 2023b; NIST, 2024). In this regard, clinical pathway initiatives for HPO systems such as familial hypercholesterolemia are supported by academia, science, and medicine, along with genome education on predictors and intercepts (Genomics Education, 2024; Chora and Bourbon, 2021). National AI evaluations of biological models and AIDRS project developments benefit from digital record pre-eXam and eXam classifications (NIST, 2024; The AI and digital regulations service, n.d.). The AIDRS authorities in research [HRA], regulation [MHRA], commission [NICE], and governance [CQC] may:

For well-being and welfare assessment, the proposition is that AIDRS authorities recommend agile group developers with X approval for adoption. The HEMSS provides public inclusivity and stakeholder engagement for developers to access data and for adopters to govern classification adherence. HEMSS further evaluates and acts on biobank opportunities for well-being and welfare value-based care by sustaining the digital PHM grid with:

PHM disease segmentation is a healthcare tool that aligns intercepts and resources of common health conditions, such as agile grouping (Wood et al., 2023). However, the need for alignment in risk stratification necessitates demonstrating how disordered agile groupings can be practically applied (Wood et al., 2023). Cohorts present barriers to stratification and segmentation reforms, while valid HPO classifications improve public health outcomes and reduce adverse patient events (Chigboh et al., 2024). Biological models are built for integration with HPO, utilizing predictive health multi-omics pre-eXams to enable digital eXam intercepts as a reflex Gen AI response (NIST, 2024). Table 2 expands the real-world instances of predictive pre-eXam and eXam intercepts, detailing HPO activities.

The simplicity of PHM risk stratification of disease segmentation and its application to real-world HPO instances should keep our practitioners and readers engaged in the bigger picture of reform. Figure 1 depicts the HEMSS governance of classifications, adherence to predictor and intercept adoption, engaging stakeholders, and ensuring public inclusivity. These principles address broader socio-economic challenges. Figure 2 shows how PHM opportunities for HPO enhance quality of life and reduce premature deaths through contributions to the pre-eXams and eXams phases, ultimately mitigating community and global environmental risks through personalized plans for well-being and welfare. Figure 3 illustrates and reminds our society that the path to implementing reform follows steps including welfare and well-being evaluations of standard approaches for PHM, with an assessment of toolkit approaches for HPO.

Quality data standards input heterogeneity for HPO output which interoperate with AI to predict and intercept pathology through FDPs in a safe space with a panoramic view of health for personalized plans (DHI Newsteam, 2022; Miandoab et al., 2023). Mature standards for interoperability provide advanced PHM opportunities.

Figure 2 shows the agile group developers who securely share and manage health information for the PHM of the HPO. The HIMSS Infrastructure Adoption Model (IFRAM) measures healthcare maturity, guiding organizations to optimize technology investments and improve outcomes (Healthcare Information and Management Systems Society, 2019; HIMSS, 2024b). The AMRAM evaluates the maturity of healthcare organizations in their use of analytics (HIMMS, 2021). The e-medical Record Adoption Model (EMRAM) guides the adoption of EHRs aimed at digital maturity and improved patient care (HIMSS, 2024a). HIMSS-EMRAM level 7 has robust analytics capabilities and strong data governance and uses technology for operational performance and best outcomes (Celebrating HIMSS stage 7 organizations advancing Global Health, 2020).

The International Classification of Diseases 11th revision is the global standard developed by the World Health Organization (WHO) for coding and classifying diseases, such as ORPHANET for rare disorders and related problems, to enhance diagnostic accuracy and support interoperability with modern digital systems (World Health Organization, 2022; GOV.UK, 2021). The ICD-10 is an earlier version that is widely used for coding and classifying medical diagnoses and mortality data to provide a common language for recording and reporting diseases (GOV.UK, 2021). HL7-FHIR is the norm for electronically exchanging healthcare information, promoting interoperability and seamless data sharing across ecosystems to improve healthcare delivery (HL7UK, “FHIR®,” HL7 UK, 2023).

Figure 1, Column 3 depicts HEMSS standards and tools for PHM predictive health pre-eXams and precise care eXams for each HPO. Biological modelling supports HPO understanding to advance ICD into safe HPO space (NIST, 2024) for dimensional points of need (Institute of Biomedical Sciences, 2023). HIMSS Level 7 ensures robust analytics capabilities and strong data governance, facilitating the use of advanced AI tools for improved patient outcomes (Celebrating HIMSS stage 7 organizations advancing Global Health, 2020). HEMSS agile groups further advance opportunities for the PHM of HPO classification stewardship in reforms on issues from rare infant diseases to non-communicable conditions with predictor pre-eXams and intercept eXams as the Gen X norm (GOV.UK, 2021; HL7UK, “FHIR®,” HL7 UK, 2023; GOV.UK, 2023b).

Figure 1 shows the PHM reform with the AI toolkit evaluated by the AISI for the AIDRS, executed by the HEMSS agile groups as a task force. Figure 3 depicts the PHM transformation from “theory and assessments to strategy in pilots and reform steps” using algorithms. AI Toolkit evaluations include Section 1.3.14, Adversarial, neural, and transformer, Section 1.3.15, Generative AI and multimodal data, and Section 1.3.16, Fair Artificial General Intelligence from unbiased Gen AI.

Figure 1 Column 1 highlights the UK-US infrastructure for PHM with AISI evaluation and AIDRS. Column 2 classifies VBC at ICB and CMS points of need. Column 3 shows AI toolkits for HPO systems that predict health (pre-eXams) for precision care (eXams). Comprehensive Neural Architecture Searches (NAS) and clusters deploy PHM solutions with HPO reinforcement for predictors and intercepts (Zoph and Le, 2017), as backpropagation recalibrates HPO systems in post-eXams. This approach must prioritize and optimize advanced AI infrastructure while transferring and centralizing techniques, e.g., imaging, which enhance PHM with effective and efficient HPO visions (Barret et al., 2017). Integrating NAS and patterning algorithms with evolutionary computation methods enhances PHM for HPO, examining the ongoing optimization of personalized plans with AI toolkits (Song et al., 2024).

In the left column of Table 3, pangenome Convolutional Neural Networks (CNNs) and Large Language Models (LLMs) address physical and mental health by analyzing layers and patterns in HPO systems to detect predictors and intercepts (NHSE, 2023). In the right column of Table 3, the benefits of Generative Adversarial Network (GAN) biopharma-biomarker development for HPO system personalized plans (NHSE, 2023) are enhanced by greater pan-genome specificity (Liao et al., 2023).

Regarding well-being, GANs reform genomics by employing a generator and discriminator that compete with one another, measuring uncertainty, and optimizing HPO systems (Lee and Seok, 2021; Kim and Lee, 2023; Lee and Seok, 2019). These efforts have yielded landmark findings regarding gene expression (Lee, 2023). The GAN genome builds sustained features for PHM, reiterating complex patterns such as haplotypic structure and linkage disequilibrium (McVean and Kelleher, 2019). Pangenome specificity with GANs enhances the scientific aspects of nucleotide building, translating transcript machinery to proteins, advancing drug discovery, targeting binding affinity, and drug-to-drug interactions (Koutroumpa et al., 2023; Gangwal and Lavecchia, 2024; Kalemati et al., 2024; Tang et al., 2024), including epigenetic reflex testing, such as methylation (Sabrin Afroz et al., 2024).

We can picture CNNs in pre-eXam presentations of HPO nucleotide layers for motifs such as promoters, transcription factors, and epigenetic markers (Koo and Eddy, 2019). Concurrently, our researchers undertake extensive biological imaging for evidence-based routine services, which empowers personalized medicine with eXam intercepts and monitoring (Koo and Eddy, 2019; Galić et al., 2023). Indeed, the future of advanced medical pathology imaging provides the best patient benefits by backpropagating massive national outcome data sets (Sarvamangala and Kulkarni, 2021; Wang, 2024).

Regarding welfare, we transgress social science factors and environmental elements. LLMs are ideal for defining each HPO system within the biomedical and clinical domains (Yang et al., 2023), expanding a biological model with socio-environmental phenomena (NIST, 2024; Ziems et al., 2023). HPO systems align LLM data with HPO bioinformatics, biological models, and the social sciences (Ziems et al., 2023; Park et al., 2024; NIST, 2024). The vast increase in scientific LLM literature supports the aim to unravel PHM further (Authors, n.d.; Ding et al., 2023). Indeed, a future perspective of PHM assesses a biological model with clinical knowledge and social sciences using quality data and continuous integration for fair HPO (Manning et al., 2024; Singhal et al., 2023; Gallegos et al., 2023).

Reform is a toolkit of promises in need of ecosystem thinking, wherein Generative AI improves organizational PHM capability to innovate and realize HPO risk stratification and condition segmentation (Wachter and Brynjolfsson, 2023). AI empowers health and social care to optimize performance and improve communication, providing novel insights into enhancing public health decision-making and outcomes (Bharel et al., 2024). The integration of Gen-AI in healthcare streamlines HPO flow for diagnostic accuracy and personalized treatment plans, advancing patient care and operational efficiency (Reddy, 2024). Gen AI models like transformers or diffusion models are reshaping predictive health and precision care. The eXams, digitally twinned from pre-eXam insights and alert to drug design or therapeutic targeting, may be guided by HPO imaging (Shokrollahi et al., 2023).

In Table 4, the PHM Gen AI multimodal data in genomics, images, and patient records feature HPO predictors for accurate intercepts. In Table 4, value-based care at points of need build genome biology models as socioenvironmental elements differentiate each HPO as a system.

In Figure 2, the HPO is centered on Gen AI and realized across sectors using synthetic or real-world multimodal data, wherein ecosystem analytics for GANs, CNNs, and LLMs are operational (Bragazzi and Garbarino, 2024). NHS Genomic England governs the “blueprint” that characterizes insights, initiating risk stratification for predictors while segmenting conditions for intercepts with value-based care at the point of need for truth (Institute of Biomedical Sciences, 2023).

Figure 3 shows the steps to PHM for HPO, while quantum intelligence will execute the WHO-UN promise to improve well-being by mitigating patient risks for socioeconomic growth (United Nations, 2023; U. Environment, 2021). A balance of what is fair in public health and welfare edges Gen AI within Q-Star and Sonnet 3.5 projecting biological modelling toward digital HPO expertise (Indian Express, 2023; NIST, 2024). PHM with quantum ML advances complex data handling through fault tolerance to sustain health goals (Wang and Liu, 2024; United Nations, 2023). Agentic AI involves continuous HPO monitoring in a post eXam phase which also mitigate bias, as explained below.

Meanwhile, the fairness of quantum Agentic AI in national access and the use of personal data must determine the moral intentions for sustaining people in decent work if we are truly to sustain well-being and welfare (UK Parliament, 2024; United Nations, 2023; U. Environment, 2021).

In the realm of well-being, medical errors have been identified as the third leading cause of death, with the epidemiology of malpractice claims significantly impacting health and socioeconomic growth (Makary and Daniel, 2016; Wallace et al., 2013). While it is human to err, our practitioners adhere to the “first do no harm” principle in building a safer health and care ecosystem (Kohn et al., 2000).

In Table 5, population health management of human phenotype ontologies as a strategy for UK healthcare reform lays the foundation for theories to construct ecosystem excellence for public health, patient safety, and parity (NHSE, 2024). The UK Department of Science, Innovation, and Technology are designing a robust infrastructure with key recommendations for science and technology to reform populace health (GOV.UK and DSIT, 2024).

Figure 3’s right-hand side illustrates the PHM strategy as a series of detailed reform steps, which are explained as follows. Section 1.3.18 conceptualizes UK clinics and US federal reform classifiers. Section 1.3.19 outlines the planning of privacy for data access and use of genomic biobanks. Section 1.3.20 details the action plan for DNA democratization, safe public health, and cybersecurity. Section 1.3.21 discusses governing boards and services in a PHM reform and Section 1.3.22 outlines the scaling of higher expert medical science safety with agile groups.

In Figure 3, the first step to reform involves conceptualizing UK clinics and US federal reform with populace health classifiers that deploy fit-for-purpose analytics as primary HPO healthcare. Fully understanding primary care reform is an international effort to address heterogeneity of aging in biological medicine and to classify genome predictive and diagnostic health in the pre-eXam (Henderson et al., 2023). PHM resources streamline processes, improve transparency, eliminate duplication, and mitigate variations in practice to accelerate concise and accurate eXam intercepts and reduce health disparities for outcome excellence in a lifetime (Wise, 2024). Table 6 aligns UK-US clinic services with a global focus on new PHM themes that realize HPO value-based care at points of need.

The US CMS provides extensive data access through Data.CMS.gov, which collects and shares data on Medicare and Medicaid beneficiaries, highlighting steady enrolment increases of healthcare providers and citizen service users (Data.CMS.Gov, n.d.). Other HPO data under the “CMS Innovation Centre Programs” appears fragmented (Data.CMS.Gov, n.d.). Multiple datasets improve patient care and reduce costs, with CMS developers accessing biobanks and primary care data for the PHM of HPO through the Million Veterans and All of Us Programs sourced with genomics and socio-environmental informatics (Gaziano et al., 2016; NIH, 2024; CMS Developer, 2024).

The Health Insurance Portability and Accountability Act privacy rule ensures that patient data are protected and used appropriately, as provided in the summary of the privacy rule (U.S. Department of Health and Human Services, 2022). Although the benefits of PHM are evident, they must operate within HIPAA’s strict data privacy and security standards to protect patient data and use them appropriately with the components of a model representative of HPO (Team DataMotion, 2019). HIPAA sets national standards for protecting Protected Health Information (PHI), ensuring that data privacy and security are maintained while allowing the flow of health information needed for high-quality care (OCR, 2008). HIPAA regulations require detailed attention, with checklists available for comprehension and adherence to new data security measures that may affect biobank data use (HIPAA Journal, 2022).

The UK Integrated Care Ecosystem and ICBs are responsible for protecting the privacy of identifiable information and ensuring that data sharing between healthcare providers complies with the Data Protection Act 2018 and the UK GDPR (GOV.UK, 2018). Developers must implement robust data protection measures, such as encryption and access controls, to safeguard patient information and ensure data is handled securely and transparently within a PHM ecosystem; failure to comply with these regulations could result in corrective actions, sanctions, and penalties (Information Commissioner's Office, 2023). Biobank agile groups in the UK must adhere to standards that protect their HPO data, while adopters of PHM must be aware of the impact of new legislation.

In Figure 3, the steps for PHM use of UK-US biobanks are shown to prioritize privacy for individuals, who should understand and agree on how personal data are used for HPO well-being. HIPAA requires covered entities to obtain patient consent for the use and disclosure of PHI while mandating authorization for the use or disclosure of PHI not otherwise permitted by the Privacy Rule, ensuring that patients are informed about how their data will be used and shared (U.S. Department of Health and Human Services, 2022; Team DataMotion, 2019; OCR, 2008; HIPAA Journal, 2022). The UK Data (Use and Access) Bill enhances data governance and transparency, with provisions for informed consent and explicit authorization from individuals to use their data involving AI and digital processes such as PHM, which would be required (GOV.UK, 2023a).

The Acts and Bills with which authorities aim to address privacy with AI in decision-making while ensuring transparency and fairness support the development of a data ecosystem that promotes well-being and drives socioeconomic growth (U.S. Department of Health and Human Services, 2022; Team DataMotion, 2019; OCR, 2008; HIPAA Journal, 2022; GOV.UK, 2023a; UK Parliament, 2024). The PHM’s potential to exchange data across international borders and maximize data aggregation to enhance equality and global health is most feasible with anonymized data and citizen-informed consent to support a worldwide HPO standard of care with federated Antigenic AI learning (Köhler et al., 2021).

On new frontiers, science and technology reforms are accelerated by engaging boundaries for DNA use, providing evidence for PHM to predict and intercept HPO with government cybersecurity guardrails (Schumacher et al., 2020; GOV.UK and DSIT, 2024). Genomic tests for disease must be cyber-secure, as we strive for DNA passports and quality lives that maintain good health and data protection while negating vulnerability (Bilkey et al., 2019; Mayeur et al., 2023). The UK and US MoU for AI in PHM aims for safe science and secure technology to ensure global health and individual privacy (UK.GOV, 2024). Citizen mistrust or perceptions of transparency may lead individuals to refuse genome access, although DNA democratization with or without passports ensures an identification legitimacy within a safe well-being space (Mayeur et al., 2023; Tommel et al., 2023), which HEMSS strives for.

As shown in Figure 1, standard data AI tools with agile groups develop HPO in cybersecure classifications that protect against threats while being transparent and unbiased. The National Science and Technology Governance of PHM disease segmentation for nucleotide-HPO intercepts introduced another X dimension for privacy, security, and health parity (Department for Science, Innovation & Technology, 2024). The joint AISI pre-deployment biological models evaluate the safety and security needs for cyber-secure PHM ecosystems, as Gen AI aligns biological questions with answers (NIST, 2024). Safe public health in a cyber-secure nation involves test evaluation cycling through vulnerability, discovery, and exploitation to ensure robust operations, agile ecosystem environments, and seamless attack planning and execution (NIST, 2024).

In the UK, audits in the healthcare sector and community assessments contribute to a more extensive set of data alliances, evaluating informatics for quality improvement (Healthcare Quality Improvement Partnership, 2024; NHS England, 2019; NHS England, 2017; UK Health Data Research, 2024). Genomic data are a promising aspect of the future of NHSE assessment of ICBs, with accountability in evaluating PHM performance to improve well-being as a national strategic priority (N. England, 2023; Genome UK, 2022). The UK Rare Diseases and Major Conditions unit’s prediction and intercept arrangements (GOV.UK, 2021; GOV.UK, 2023b) benefit profoundly from infant studies and adult programs that build on biological modelling (NHS England, 2024; Our Future Health, 2021). The truth is that UK organizations are not prepared for the PHM of the HPO, so the HEMSS is necessary to ready reform in a UK-US MoU (Figure 1).

Oversight in HPO reform uses a new global pan-genome reference to accelerate genomic specificity and enrich value-based care (National Human Genome Research Institute, 2023; NHS England, 2022). The UK government’s direction in neighborhood clinic reform is to direct resources to primary care, which benefits from the HEMSS principles (Anderson, 2024) (Figure 1, Column 2). Meanwhile, the NHSE infrastructure with QA governance developed a digital genomic directory service for HPO predictors and intercept services as an agile group development (NHSE, 2024; C. Office, 2023). Meanwhile, value-based care in the UK-US MoU aligns social determinants with genomics, benefiting the US Center for Medicare and Medicaid Innovation (Holland and Knight, 2024; Office of Disease Prevention and Health Promotion, 2023), as both projects deliver on the Biological Model (NIST, 2024).

The US Department of Health and Human Services supports structured knowledge as CMS surveys aim to mitigate premature deaths and unnecessary emergency department arrivals (Authors, 2023; Centers for Disease Control and Prevention, 2019). Risk factor surveillance is misplaced in disease control, while PHM for HPO in a HEMSS toolkit benefits CMS federal centers with value-based care (Figure 1). Federal Center PHM of the HPO model will implement value-based primary care by incorporating risk scores and pharmacogenomics as pre-eXam model queries, wherein the X will detail the particulars of the query as the point of truth or probability (Lewis et al., 2024; CMS.GOV, 2023a; Collister et al., 2022; Sarwar, 2023). With over 1 million registrants in the “All of Us” program a national PHM reform has commenced (All of Us Research Hub, 2024). Therefore, HEMSS principles and classifications for the UK-US joint aim to model HPO (NIST, 2024) as reform classifiers to initiate controlled change (Figure 1).

UK and US healthcare services face increasing demand, complexity, costs, and competencies that benefit PHM economically by scaling science and technology (Spanos, 2024; GOV.UK and DSIT, 2024). AI’s advantage, combined with genomics’ big data veracity and velocity and the variety and volume of health determinants, presents HPO opportunities to enhance PHM (Keskar et al., 2020). The UK Infant Generation Study and digital records deepen biological models, augmenting phenotypic risk stratification and pathology segmentation and presenting an international opportunity (Horton et al., 2024).

The International Genome Health pre-eXam and our future life in science infrastructure, with authority and directorship (Figure 1), guide HPO policy projects using HEMSS agile groups (Figure 2) and fit-for-purpose reform steps (Figure 3). The PHM of rare infant diseases extends to non-communicable condition predictors with practical and ethical intercepts as the population health projects reform services in diagnostics and conventional medicine (Population Health Analytics Laboratory, 2024). In medical specialty analytics such as hematology and cardiovascular disease, HEMSS agility and stewardship pilot Gen AI proof-of-concept with biological commissioning scaling population health excellence (The Royal College of Pathologists, 2020). Consider the following depictions:

The pathological pilots align with other WGS predictors to provide a differential diagnosis between biological and HPO models. The PHM of HPO commission and adopt excellence in national multi-omics, imaging and social determinants for primary stakeholders in the Genomics England, the Royal Colleges and bio-banks as the AI laboratory services develop with the proposed HEMSS stewardship which align ecosystem digital approaches (Population Health Analytics Laboratory, 2024; The Royal College of Pathologists, 2020; Royal College of Pathologists, 2022).

From a UK perspective, NHSE and Genomics England actively incorporates PHM as a central strategy across ICBs to transform a reactive healthcare system into a proactive ecosystem, addressing inequalities and optimizing outcomes (NHS England, 2021b). The delay in providing patient data to biobanks is due to the need for a federated learning ecosystem for PHM processing, where the choice of critique may cite ethical, social, and regulatory prerequisites (Rumbold and Pierscionek, 2017). Nevertheless, practitioners and the public must consider the moral and societal positive implications of PHM to determine the HPO (Yurkovich et al., 2023; Hiam et al., 2024). Table 7 presents the ethical debates on integrating HPO reform into primary care.

As Figure 3 shows, implementing reform steps in PHM for the HPO has societal implications involving bias, patient autonomy, and public engagement in decision-making regarding AI predictors and intercepts. Table 8 discusses the societal impacts of the AI PHM toolkit for public HPO, inclusivity, and stakeholder engagement while governing the classifications for adherence to HEMSS principles.

In Table 1, HEMSS principles support global attitudes and behaviors for PHM as NHSE and Genomics England plans digital test directories for universal points of need (NHS England, 2021b; Institute of Biomedical Sciences, 2023; C. Office, 2023). Indeed, as a prelude to PHM, the WHO evaluated the Healthy City Program and highlighted its impact on urban health and policies (de Leeuw et al., 2015). Many PHM studies have developed themes for trust in the vision of shared ownership and goals, with place-based accountable transformation to an ecosystem (Siegel et al., 2018; Pimperl, 2018; Greater Manchester Integrated Care Partnership, n.d.), whereas the HEMSS stewardship systemizes HPO for global health inclusiveness.

The WHO Focus Group for evaluating standard AI health solutions interfaces ML, medicine, regulation, public health, and ethics (United Nations, n.d.) with HEMSS principals, engaging stakeholders on reform to UN SDGs (United Nations, 2023; U. Environment, 2021). Meanwhile, a PHM ecosystem with newer pangenomes determines HPO specificity, providing safer predictors and intercepts (Petrić Howe and Bundell, 2023). Moving with the WHO’s six principles, the direction intensifies on the genome and social science in public health inclusiveness with national engagement to optimize the PHM of HPO through HEMSS future directions (Jasarevic, 2021; Benjamin et al., 2024).

Furthermore, the WHO cautions against using AI in poorer nations, speculating that the UK-US should lead global initiatives, whereby the HEMSS is ideal for the PHM of HPO reform with evidence-based outcomes (Adam, 2024). Looking through the lens of heterogeneity, HPO are associated with scientific features that predict health and inform intercepts through a classical approach (Woodward et al., 2022). UK NHSE AI Ops, Genomics England, and the US NIH alignment for AISI/NIST open biological models, while HEMSS simplifies science and technology reform with a “classical” progress unique to national HPO integration (Department of Science, Innovation and Technology, 2023; Human Phenotype Ontology, n.d.).

Figure 1 depicts the development of GEN AI for adoption in primary care reform. In Column 2, HEMSS principles deploy value-based care through public inclusiveness and stakeholder engagement in the governance and adherence to fit-for-purpose classifications at the point of need. In Column 3, the HEMSS standards and tools for the UK ICB and US CMS execute the classical predictive health pre-eXams and eXam intercepts, with each X explaining world HPO health and what nations choose to adopt for their PHM development.

Figure 3 harmonizes the reform steps and pilots involving US-UK partners in AI Safety focused on biological modelling for personalized predictors and intercepts (NIST, 2024). The MoU for AI establishes the AISI for the future of HPO, with pilot projects through the AIDRS with Genomics England, biobanks, Google, DeepMind, and OpenAI (US Department of Commerce, 2024; NHS Beta, n.d.; Care planning, 2024). HEMSS stewards the classifier phases in personalized predictive health pre-eXams and precise care eXam intercepts.

Figure 2 harmonizes value-based care points of need for HPO-centered healthcare that is safe, fair, transparent, trustworthy, and engages organizations overseen by UK ICBs and the US CMS underpinned by national health initiatives. PHM develops from Trusted Research Environments, with UK NIHR and US NIH engaging in clinical pathway initiatives, using specialist genomics to develop ecosystem PHM of HPO with Agentic AI stewards of classifications (National Institute for Health and Care Research, 2024; National Institute of Health, 2024b).

Figure 1 harmonizes the reform columns for the PHM-HEMSS agile group development, featuring multiple authorities that align into more refined services with authority for HPO research, regulation, commission, and stewardship underpinned by Generative AI in quantum futures. Table 9 shows the changing landscape, as the management of populace health will realign national services that harmonize with digital identity.

As Figure 2 shows, the HPO policy stewards the predictive health pre-eXam development and precise care eXam adoption in an ecosystem of fit-for-purpose classification adherence and monitoring. Roadmaps for digital transformation in the UK and US align with HPO service reviews to consider PHM regulations or accreditation with access and the reuse of data for value-based care at a point of need (Transformation Directorate, n.d.; National Institutes of Health, n.d.). The debates follow the themes regarding accreditation and regulation in Table 10, and a discussion summary follows.